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Experimental autoimmune encephalomyelitis (EAE) is a demyelinating pathology of the central nervous system (CNS) used as a
model to study multiple sclerosis immunopathology. EAE has also been extensively employed to evaluate potentially therapeutic
schemes. Considering the presence of an immune response directed to heat shock proteins (hsps) in autoimmune diseases and
the immunoregulatory potential of these molecules, we evaluated the effect of a previous immunization with a genetic vaccine
containing the mycobacterial hsp65 gene on EAE development. C57BL/6 mice were immunized with 4 pVAXhsp65 doses and 14
days later were submitted to EAE induction by immunization with myelin oligodendrocyte glycoprotein (MOG
35–55) emulsified
in Complete Freund’s Adjuvant. Vaccinated mice presented significant lower clinical scores and lost less body weight. MOG
35–55
immunization also determined less inflammation in lumbar spinal cord but did not change CD4+CD25+Foxp3+ T cells frequency
in spleen andCNS. Infiltrating cells from the CNS stimulated with rhsp65 produced significantly higher levels of IL-10.These results
suggest that the ability of pVAXhsp65 vaccination to control EAE development is associated with IL-10 induction.
1. Introduction
Multiple sclerosis (MS) is a progressive inflammatory disease
that damages the brain and the spinal cord. A plethora of
reports support the view that it is mediated by autoreactive
T cells specific for myelin antigens [1, 2]. Once they had been
activated in the periphery, these self-specific T cells cross the
blood-brain barrier and destroy the myelin sheets and axons
from central neurons [3–5].This demyelination is responsible
for signal conduction slowing or even signal blockage [6].
Currently available therapies for MS are primarily focused
in minimizing the progression of disability and reducing the
number of relapses. The standard first-line immunomodula-
tory therapies include IFN-𝛽 and glatiramer acetate [7, 8].
Other drugs as natalizumab and fingolimod are also effective
in lowering recurrence rates and slowing disease progression
[9]. Experimental autoimmune encephalomyelitis (EAE) is
an induced demyelinating pathology of the central nervous
system (CNS) that is commonly used as amodel to investigate
this disease. EAE is triggered in susceptible mouse and rat
strains by immunization with myelin proteolipid protein,
myelin basic protein, or myelin oligodendrocyte glycopro-
tein (MOG
35–55) emulsified in Complete Freund’s Adjuvant
(CFA) [10–12].Thesemodels and also human studies indicate
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that many cell subsets as Th1, Th17, Tc, and T𝛾𝛿 contribute to
damage of the CNS [1, 13]. More recently, subsets of T cells
endowed with immunoregulatory ability were characterized
and their contribution to restrain self-reactivity is being
established. Regulatory T cells (Treg cells) encompass both
natural and inducible (adaptative) cell types. Natural Treg
cells are identified by high CD25 expression and intracellular
presence of the forkhead box P3 (Foxp3) transcription factor,
which is required for directing regulatory function [14].These
cells were originally identified by their ability to establish
tolerance to self-antigens [15]. Natural Treg cells develop
in the thymus after expression of Foxp3 at a relatively late
stage of thymopoiesis [16]. Adaptive Treg cells including Tr1,
Th3, and various CD8+ Treg cells subsets are triggered by
stimulation of na¨ıve T cells by their cognate antigens (self or
nonself) in the periphery. Suppressive cytokines as IL-10 and
TGF-𝛽 contribute to both induction of these Treg cells and
also stimulation of their suppressive function. Tr1 cells exert
their suppressive function primarily through IL-10 secretion
[17] whereasTh3 cells act mainly through TGF-𝛽 release [18].
Even though current therapies for MS are limiting the
impact of this neurodegenerative disorder, they can cause
severe side effects as cutaneous lesions [19], depression,
thyroid dysfunction, cardiotoxicity, liver enzymes abnormal-
ities, and increased susceptibility to infections [20]. The
production of anti-drug antibodies has also been described
[21]. Novel disease modifying therapies are being tested
as monoclonal antibodies, chimeric molecules, and oral
therapies [22, 23]. Prophylactic and therapeutic approaches
based on Treg cells induction would be highly useful. Even
though antigen-specific Treg cells would be preferentially
indicated, other Treg cells subsets are being examined. Heat
shock proteins (hsps), for example, are being considered as
potential targets for the treatment of inflammatory diseases
due to their increased expression in inflammatory foci. This
possibility is supported by convincing evidence that hsps
can induce immunoregulatory T cell responses [24–27]. The
immunomodulatory ability of the mycobacterial hsp65 in
autoimmune diseases has been demonstrated by us and
other authors in arthritis [28, 29], diabetes [30–32], and
atherosclerosis [27, 33].
More recently, we also tested the immunomodulatory
potential of pVAXhsp65 (a genetic vaccine containing the
hsp65 mycobacterial gene) in EAE. Initially it was applied
therapeutically, that is, after disease induction. Even though
this approach was able to significantly downmodulate the
peripheral production of encephalitogenic cytokines, it was
not capable of reducing disease severity [34]. Considering
that memory and naı¨ve T cells could present a differential
susceptibility to regulation [35], we supposed that na¨ıve T
cells, specific for MOG
35–55 and present in mice not yet
submitted to EAE induction, could be more responsive to
regulation by hsp65. We therefore tested the prophylactic
potential of pVAXhsp65 on EAE development.
2. Materials and Methods
2.1. Experimental Procedure. A preliminary experiment was
done to choose the immunization protocol with the highest
immunoregulatory potential. Mice were injected with 2, 3,
or 4 doses of pVAXhsp65 with 14 days being the interval
between doses. The animals were euthanized 14 days after
the last dose and IFN-𝛾 and IL-10 were quantified in spleen
cell cultures stimulated with recombinant hsp65 (rhsp65).
Mice injected with saline were used as a control group.
To evaluate the prophylactic effect of pVAXhsp65 on EAE
development, mice were immunized with 4 pVAXhsp65
doses and 14 days after last dose they were submitted to EAE
induction. Disease development was evaluated by clinical
follow-up (clinical score and weight variation) and also by
histopathological analysis of the CNS. The immunoregula-
tory potential of pVAXhsp65 vaccination was checked by the
profile of cytokine production by spleen and CNS infiltrating
cells stimulated with MOG
35–55 or rhsp65 and also by the
presence of Foxp3+ regulatory T cells in these two organs.
Mice injected with saline (control) or with the empty vector
(pVAX) were used as control groups.
2.2. Animals. Female C57BL/6 mice (4–6 weeks old) were
purchased from CEMIB (UNICAMP, Sa˜o Paulo, SP, Brazil).
The animals were fed with sterilized food and water ad
libitum and were manipulated in accordance with the eth-
ical guidelines adopted by the Brazilian College of Animal
Experimentation. Animal experiments were conducted with
the approval of the Ethics Committee for Animal Experimen-
tation, Medical School, Universidade Estadual Paulista.
2.3. DNA Vaccine Encoding hsp65 Assembly. The vaccine
pVAXhsp65 was constructed from the pVAX vector (Invit-
rogen, Carlsbad, CA, USA). This plasmid was digested
with BamHI and NotI (Gibco BRL, Gaithersburg, MD,
USA) and then the M. leprae hsp65 gene and the CMV
intron A were inserted. DH5𝛼 E. coli transformed with
pVAX or pVAXhsp65 were cultured in LB liquid medium
(Gibco BRL, Gaithersburg, MD, USA) containing kanamycin
(100 𝜇g/ml). The plasmids were purified using the Concert
High Purity Maxiprep System (Gibco BRL, Gaithersburg,
MD, USA). Plasmid concentrations were determined by
spectrophotometry at 𝜆 = 260 and 280 nm by using the Gene
Quant II apparatus (Pharmacia Biotech, Buckinghamshire,
UK).
2.4. Recombinant hsp65 Protein (rhsp65). The rhsp65 was
obtained from Escherichia coli ER2566 previously trans-
formedwith the hsp65 gene fromM. leprae.The transfectedE.
coli was cultured in LB containing ampicillin (100 𝜇g/𝜇l) and
the bacterial growth was monitored by spectrophotometry
at 600 nm. When the optic density reached a value of 0.6,
the culture was induced with isopropylthiogalactoside 0.1M
(Gibco BRL, Gaithersburg, MD, USA) and incubated at 30∘C
under agitation for 4 h. Details of rhsp65 production and
purification can be found at dos Santos et al., 2010 [36].
2.5. Vaccination with pVAXhsp65. Mice were injected with 4
doses of pVAXhsp65 (100 𝜇g/100 𝜇l) by intramuscular route
(quadriceps muscle). Fourteen days after the last dose the
animals were submitted to EAE induction.
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2.6. EAE Induction. MOG
35–55 peptide (MEVGWYRSPFS-
RVVHLYRNGK) was synthesized by Proteimax, Sa˜o Paulo,
Brazil. EAE was induced as previously reported [37]. Briefly,
mice were immunized with 150 𝜇g of MOG
35–55 emulsified
in CFA containing 400 𝜇g of BCG. Two doses of 200 ng
of Bordetella pertussis toxin (Sigma Aldrich, St. Louis, MO,
USA) were administered by intraperitoneal route. Animals
were daily checked and disease intensity was recorded as
follows: (0) no symptoms, (1) limp tail, (2) hind legsweakness,
(3) partially paralyzed hind legs, (4) complete hind leg
paralysis, and (5) complete paralysis/death.
2.7. CNS Infiltrating Mononuclear Cells Isolation. Mononu-
clear cells infiltrated in the CNS were obtained as pre-
viously described by Mimura et al., 2016 [38]. Briefly,
sedated (ketamine/xylazine) mice were perfused with saline
solution and then brain and the whole spinal cord were
collected, macerated, resuspended in RPMI medium (Sigma
Aldrich) supplemented with 2.5% collagenase D (Roche
Applied Science) and incubated at 37∘C, 5% CO
2
incubator
for 45min. Cells were then resuspended in percoll (GE
Healthcare) 37% and gently laid over percoll 70%. After
centrifugation at 950×g for 20min the ring containing
mononuclear cells was collected. Cellular suspension from
percoll interface was then resuspended in supplemented
RPMI medium (1% gentamicin, 2% glutamine, 1% sodium
pyruvate, 1% nonessential amino acids, and 10% of fetal calf
serum).
2.8. Spleen and CNS Cell Culture Conditions. Spleen and
mononuclear cells isolated from the CNS were adjusted
to 5 × 106 cells/ml and 2 × 105 cells/ml, respectively, and
cultured in supplemented RPMI medium. Spleen cells were
restimulated in vitro with MOG
35–55 (20𝜇g/ml) or rhsp65
(10 𝜇g/ml), while CNS-isolated cells were stimulated with
MOG
35–55 (50 𝜇g/ml) and rhsp65 (10 𝜇g/ml). IFN-𝛾, IL-
10, IL-6, IL-17, and TNF-𝛼 levels were assessed in culture
supernatants by ELISA (Becton Dickinson, San Jose, CA,
USA, and R&D Systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions.
2.9. Proportion of CD4+CD25+Foxp3+ T Cells. Spleen cells
were collected and the red blood cells were lysed with Hank’s
buffer containing NH
4
Cl. Spleen and CNS infiltrating cells
were adjusted to 2.5 × 106 cells/100 𝜇l and then incubated
0.5 𝜇g of FITC labeled anti-mouse CD4 (clone GK1.5) and
0.25 𝜇g of APC labeled anti-mouse CD25 (clone PC61.5)
at room temperature during 20min. A staining for Foxp3
was performed using the anti-mouse/rat Foxp3 Staining
Set (eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. The cells were analyzed by flow
cytometry using the FACSCanto II (Becton Dickinson, San
Jose, CA, USA) and FACSDiva software (Becton Dickinson,
San Jose, CA, USA) at Amaral Carvalho Foundation (Jau´, Sa˜o
Paulo, Brazil).
2.10. Inflammatory Infiltration in the CNS. The histological
analysis was performed in the CNS at the 30th day after
EAE induction. Lumbar spinal cord samples were removed
and fixed in 10% neutral buffered formalin. Paraffin slides
with 5 𝜇m were stained with hematoxylin and eosin (H&E)
and analyzed with a Nikon microscope. A semiquantita-
tive analysis of CNS inflammation was performed accord-
ing to the following criteria: (0) no infiltrates; (1) partial
meningeal infiltration; (2) pronounced meningeal infiltra-
tion; and (3) pronounced meningeal and some parenchymal
infiltration as already adopted by us and other authors [39,
40]. This evaluation was done with a Nikon microscope
by analyzing two distinct areas in the samples of each
animal.
2.11. Statistical Analysis. Data were expressed as mean ±
SE. Comparisons between groups were made by one-way
ANOVA with post hoc Holm-Sidak test for parameters with
normal distribution and by Kruskal-Wallis followed by a post
hoc Dunn’s test for parameters with nonnormal distribution.
Significance level was 𝑝 < 0.05. Statistical analysis was
accomplished with SigmaStat for Windows v 3.5 (Systat
Software Inc).
3. Results
3.1. Immune Response Induced by pVAXhsp65 Immunization.
Immunization with 2, 3, or 4 pVAXhsp65 doses determined
the production of similar amounts of IFN-𝛾 (Figure 1(a))
by spleen cells stimulated with rhsp65. However, only 4
pVAXhsp65 doses triggered a significant IL-10 produc-
tion (Figure 1(b)) by these cells. These high IL-10 levels
were not, however, associated with a higher frequency of
CD4+CD25+Foxp3+ T cells in the spleen. The proportion of
these cells, evaluated 14 days after DNA immunization, was
similar in immunized, injected with vector or noninjected
experimental groups (Figure 1(c)).
3.2. Decreased EAE Severity in Mice Previously Immunized
with pVAXhsp65. Previous immunization with pVAXhsp65
significantly reduced EAE symptoms. By the 17th day of the
disease, when the paralysis achieved its maximum level in the
EAE control group (clinical score = 3), the average score in the
previously immunized group was 1.5. Previous vaccination
also delayed disease onset and determined lower clinical
scores during the chronic disease phase (Figure 2(a)).The sta-
tistical significance of clinical improvement was determined
by linear regression analysis (Figure 2(b)). Besides, mice
previously immunized with pVAXhsp65 lost significantly less
weight than the EAE control group (Figure 2(c)).
3.3. CNS Inflammation in Mice Previously Immunized with
pVAXhsp65. Typical lesions mainly characterized by
mononuclear cell infiltration were observed in the meningeal
areas of the CNS in mice with EAE (nonimmunized)
during the chronic period of the disease. Semiquantitative
microscopic analysis indicated that previous DNA im-
munization reduced the magnitude of inflammation in the
lumbar spinal cord samples in comparison to nonimmunized
animals as illustrated in Figure 3.
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Figure 1: Immune response induced by pVAXhsp65 vaccination. C57BL/6 mice were immunized with 2, 3, or 4 pVAXhsp65 doses with 14
days’ interval. IFN-𝛾 (a) and IL-10 (b) production were assessed in spleen cells cultures restimulated in vitro with rhsp65. The percentage of
CD4+CD25+Foxp3+ T cells was evaluated in the total number of spleen cells 14 days after the last dose of pVAXhsp65 (c). Data were presented
by mean ± SE of 6 mice and are representative of two independent experiments. ∗ represents the difference between immunized and control
group. 𝑝 < 0.05.
3.4. Peripheral Immune Response in Mice Previously Immu-
nized with pVAXhsp65. Cytokine production by cultures
from different experimental groups was compared 30 days
after EAE induction. IFN-𝛾 (Figure 4(a)), IL-6 (Figure 4(b)),
and IL-17 (Figure 4(c)) produced by spleen cells from
EAE, pVAX/EAE, and pVAXhsp65/EAE groups stimulated
with MOG
35–55 reached similar levels, whereas IL-10 pro-
duction was similarly downmodulated in vector and vac-
cine previously injected groups (Figure 4(d)). A distinct
cytokine profile was observed in cultures stimulated with
rhsp65. In this case, only IFN-𝛾 levels (Figure 4(a)) were
significantly higher in the group previously vaccinated
with pVAXhsp65. Levels of IL-6 (Figure 4(b)), IL-17 (Fig-
ure 4(c)), and IL-10 (Figure 4(d)) were similar in EAE,
pVAX/EAE, and pVAXhsp65/EAE groups. EAE develop-
ment was already associated with high levels of Foxp3+
regulatory T cells in peripheral lymphoid organs and
pVAXhsp65 immunization did not augment the proportion
of these regulatory T cells in the spleen (Figure 4(e))
when compared with the control groups (EAE and pVAX/
EAE).
3.5. Immune Response at the CNS in Mice Previously Im-
munized with pVAXhsp65. A significant production of all
checked cytokines was detected in cultures from CNS
infiltrating cells. The levels of IFN-𝛾 (Figure 5(a)), TNF-
𝛼 (Figure 5(b)), IL-6 (Figure 5(c)), and IL-10 (Figure 5(d))
were similarly elevated in the three experimental groups
when the cells were stimulated with MOG
35–55. The amounts
of TNF-𝛼 (Figure 5(b)) and IL-6 (Figure 5(c)) were also
comparable in cultures from these three groups stimulated
with rhsp65. However, stimulation with rhsp65 triggered a
significantly higher production of IFN-𝛾 (Figure 5(a)) and
IL-10 (Figure 5(d)) in mice that were previously immu-
nized with pVAXhsp65. Similarly to the peripheral find-
ings, pVAXhsp65 immunization also did not increase the
frequency of CD4+CD25+Foxp3+ T cells in the CNS (Fig-
ure 5(e)).
4. Discussion
EAE is a widely employed model to understand MS
pathogenesis and also to search for prophylaxis and new
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Figure 2: Effect of previous vaccination with pVAXhsp65 on EAE development. C57BL/6 mice were immunized with 4 pVAXhsp65 doses and
then submitted to EAE induction. Kinetics of clinical scores (a), linear regression analysis of clinical scores (b), and body weight variation (c).
Data were presented by mean ± SE of 6 mice and are representative of three independent experiments. ∗ represents the difference between
immunized and control group with EAE. ∗𝑝 < 0.05 and ∗∗𝑝 < 0.001.
therapeuticmeasures towards this pathology. In this work, we
found that a genetic construction containing the mycobac-
terial hsp65 gene is endowed with prophylactic applica-
tion against EAE development. C57BL/6 mice were initially
immunized with variable pVAXhsp65 doses to choose the
potentially protective schedule. Only the 4-dose scheme was
able to prime these animals for a higher IL-10 production. As
IL-10 producer cells have been described as being induced
by rhsp65 and also able to downmodulate autoimmune
conditions [31], this vaccination procedure was chosen to
investigate the prophylactic potential of this vaccine in EAE.
C57BL/6 mice were then immunized with 4 pVAXhsp65
doses and then submitted to EAE induction. The positive
control group, that is, only subjected to EAE induction,
developed the classical signs of EAE as accentuated weight
loss and clinical paralysis. These results were expected and
very similar to what has been described by us and other
authors that used the encephalomyelitis model induced by
MOG
35–55 immunization [41–43]. Previous vaccination with
pVAXhsp65 clearly modified disease development. These
mice lost less body weight and also showed lower clinical
scores. The onset of clinical signs was likewise delayed in this
experimental group.This protective effect was also associated
with decreased inflammation at the lumbar spinal cord
suggesting reduced migration of peripheral encephalitogenic
T cells to the CNS.
Cytokine production by spleen cells stimulated with
MOG
35–55 highly suggested that the pVAXhsp65 is not
working by decreasing the peripheral proinflammatory spe-
cific immune response, as IFN-𝛾, IL-17, and TNF-𝛼 levels
were similar in all experimental groups. Intriguingly, IL-
10 levels in these cultures were significantly downregulated
in DNA injected mice. When these splenic cells were res-
timulated with rhsp65, the expected high IFN-𝛾 and IL-
10 levels previously observed in pVAXhsp65 immunized
mice were not observed. As IL-10 has been described as
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Figure 3: Effect of previous immunization with pVAXhsp65 on CNS inflammation. C57BL/6 mice were immunized with 4 pVAXhsp65 doses
and then submitted to EAE induction. Lumbar spinal cord inflammatory infiltrates in control mice without EAE (a), control mice with EAE
(b), and mice immunized with 4 pVAX (c) or pVAXhsp65 doses (d) were evaluated 30 days after EAE induction. A semiquantitative analysis
was used to assess the inflammatory infiltration (e) during the chronic disease phase.Micrographs are representative of 6 animals/group. Data
in panel (e) were presented by mean ± SE of 6 mice. ∗ represents the difference between immunized and control group with EAE. 𝑝 < 0.05.
one of the most effective anti-inflammatory cytokines in
EAE and MS [44], we reasoned that IL-10 producer cells,
specific for MOG
35–55 or hsp65, had migrated to the CNS
and partially controlled inflammation. This possibility was
tested by stimulating mononuclear cells eluted from CNS
withMOG
35–55 and rhsp65.Mice previously immunizedwith
pVAXhsp65 produced significantly higher levels of IFN-𝛾
and IL-10 in response to rhsp65, but not MOG
35–55, after in
vitro restimulation. As nonstimulated cell cultures did not
produce cytokines (data not shown), we hypothesized that
these were hsp65 specific cells. Vaccination also did not alter
the frequency of Foxp3+ Treg cells in the periphery or in the
CNS, suggesting that the classical CD4+CD25+Foxp3+ Treg
cells are not responsible for IL-10 production. It is possible
therefore that other cell types that do not express Foxp3 are
the source of this anti-inflammatory cytokine [45].
As the protocol that we used to isolate CNS cells was
based on centrifugation over discontinuous percoll gra-
dients, a variety of cells could be present in these CNS
cell cultures as neuronal cells, astrocytes, oligodendrocytes,
microglial cells, and infiltrating leukocytes, as described by
Pino and Cardona, 2011 [46]. Then, distinct specific or even
Journal of Immunology Research 7
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Figure 4: Effect of previous vaccination with pVAXhsp65 on peripheral immune response. C57BL/6 mice were immunized with 4 pVAXhsp65
doses and then submitted to EAE induction. Cytokine production was assessed 30 days after EAE induction. IFN-𝛾 (a), IL-6 (b), IL-
17 (c), and IL-10 (d) production were assayed in spleen cell cultures restimulated in vitro with MOG
35–55 or rhsp65. The percentage of
CD4+CD25+Foxp3+ T cells was evaluated in the total number of spleen cells 30 days after EAE induction (e). Data were presented by mean
± SE of 6 mice and are representative of two independent experiments. ∗ represents the difference between DNA injected groups and control
group with EAE. 𝑝 < 0.05.
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Figure 5: Effect of previous vaccination with pVAXhsp65 at the CNS. C57BL/6 mice were immunized with 4 pVAXhsp65 doses and
then submitted to EAE induction. Cytokine production was assessed 30 days after EAE induction. IFN-𝛾 (a), TNF-𝛼 (b), IL-6 (c), and
IL-10 (d) production were assayed in CNS infiltrating cells cultures restimulated in vitro with MOG
35–55 or rhsp65. The percentage of
CD4+CD25+Foxp3+ T cells was evaluated in the total number of mononuclear cells from CNS 30 days after EAE (e). Data were presented
by mean ± SE of 5 mice. ∗ represents the difference between immunized and control group with EAE. 𝑝 < 0.05.
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nonspecific cells could be the source of this regulatory
cytokine. Various cell types as macrophages, dendritic cells,
Tr1, and B regulatory cells [47, 48] are described as being able
to produce IL-10 and to contribute to EAE and MS recovery.
Many reports have also highlighted the role of hsp60/65 in
activation of B cells [49], T cells [50], Treg cells [51], and
maturation of dendritic cells [52]. Specially concerning hsp65
formulated as a DNA vaccine, Fontoura et al., 2015 [53],
described that DNAhsp65 immunization of C57BL/6 mice
induced a subtype of IL-10 producing B cell able to reduce
the production of proinflammatory cytokine mRNAs in the
spleen. Hsp65 was also able to attenuate the development
of airway hyperresponsiveness and inflammation in BALB/c
mice through modulation of dendritic cell function [54].
These findings endorse the possibility that hsp65 responsive
cells able to produce IL-10 are present in the CNS and could
mediate the protective effect observed in this work.
The vector also triggered a protective effect even though
it was discrete comparing to the one elicited by the vaccine.
This finding suggests that the immunoregulatory ability of
pVAXhsp65 partially depends upon the plasmid vector itself.
In this regard, CpGmotifs in the plasmid vector could trigger
an anti-inflammatory immune response. This possibility is
supported by some literature reports. Quintana et al., 2000
[55], showed that injection of empty plasmid DNA or CpG
oligonucleotides inhibited diabetes in NOD mice due to a
shift to Th2 profile. More recently, it has been demonstrated
that CpG-DNA sequences were capable of inducing a Th2
response in human endothelial cells through the inhibition
of proinflammatory cytokines and enhanced IL-10 expression
[56].
A similar anti-inflammatory effect of this genetic vaccine
was previously described by our research group in arthritis
[28] and diabetes [30, 31, 57] experimental models. The
potential of pVAXhsp65 as a prophylactic vaccine against
diabetes was also established by us in both homologous
and heterologous prime-boost strategies. NOD mice were
clinically protected by immunization with pVAXhsp65. The
vector also determined immunomodulation but its protec-
tive effect against insulitis was very discrete. Interestingly,
protection coincided with the influx of CD25+ cells and
increased staining for IL-10 in the islets [30]. We also
demonstrated that the combination of pVAXhsp65with BCG,
in a heterologous prime-boost protocol, was highly effective
to prevent diabetes in NOD mice [57]. In addition, we
observed that this vaccine decreased lumbar inflammation
and downmodulated peripheral IL-10 production in an EAE
rat model [12] similarly to the findings showed in the present
investigation. Again, the empty plasmid prompted a similar
but less pronounced effect. This protective effect of hsp65
in distinct inflammatory conditions is highly supported by
findings of many other authors [58–61].
Concerning EAE development, the immunoregulatory
effect of hsp65 has also been demonstrated by employing
distinct formulations containing this heat shock protein. For
example, oral administration of a recombinant Lactococcus
lactis strain that produces hsp65 prevented the development
of EAE in C57BL/6 mice. This protection was confirmed by
the reduced inflammatory cell infiltrate and absence of injury
signs in the spinal cord [62]. Also recently, Billetta et al., 2012
[63], found that intranasal treatment of EAE with the peptide
RatP2 derived from hsp60 determined a significant clinical
improvement which was superior to therapy with glatiramer
acetate.
5. Conclusion
Previous vaccination with pVAXhsp65 was able to reduce
EAE clinical manifestations and also triggered higher IL-10
production at the CNS.These findings reinforce the potential
of hsp65 to be explored as an adjuvant therapy in this and
other autoimmune pathologies.
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